Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM)
Phase 2 – studying effectiveness and dosage
Conditions:
Multiple Myeloma
Sponsor: Landspitali
trial.available_in:
БГ
Overview
Trial status: Authorised
Clinical response by IMWG, Clinical outcomes by IMWG, Safety, Correlation with correlative and clinical outcomes
Primary: Proportion of participants diagnosed with intermediate or high risk SMM that have MRD negativity three year from study enrollment
Description
Clinical response by IMWG, Clinical outcomes by IMWG, Safety, Correlation with correlative and clinical outcomes
Who can participate
Age group: 18-64 years
Gender: Female, Male
Target enrollment: 80 participants
БГ